Vaccine Testing Center

Global Health Research

The Vaccine Testing Center and laboratories are dedicated to improving global health through the development and study of new vaccines and by improving our understanding of how humans respond immunologically to infections and vaccines. In addition to vaccine testing, the lab team is interested in characterizing how the human host responds immunologically to clinically important infectious agents and vaccines. The goal of this work is to gain a better understanding of immunologic responses to vaccines as well as natural infections. Below is a sampling of both ongoing and past research.

Ongoing Vaccine Research Trials

• The Effects of Increased Inoculum on Oral Rotavirus Vaccine Imunogenicity
• Immunological Exploration- Improving Rotavirus Vaccination: Refining Correlates of Risk and Evaluating Durability
• Immunological Exploration- The Dengue Human Infection Model: Defining Correlates of Risk and Advancing Vaccine Development
• A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine in Dengue Endemic Bangladesh

Previous Research Trials

• West Nile
• Rotavirus
• Cholera
• Typhoid Fever
• Cryptosporidium infections
• Campylobacter jejuni infections

Selected Publications

• Beth D. Kirkpatrick, Stephen S. Whitehead, Kristen K. Pierce, Cecilia M. Tibery, Palmtama Grier, Noreen Hynes, Catherine J. Larsson, Beulah Sabundao, Kawswar Talaat, Marya P. Carmolli, Catherine J. Luke, Sean A. Diehl, Anna P. Durbin. The live attenuated tetravalent dengue vaccine TV003 elicits complete protection against dengue virus serotype 2 infection in a human challenge mode. Science Translational Medicine 2016.
• Kirkpatrick BD*, Durbin AP*, Pierce KK, Carmolli MP, Tibery C, Grier P, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik J, Luke C, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. *shared first author. Robust and balanced immune responses to all four dengue serotypes following a single dose of a live-attenuated tetravalent vaccine administered to healthy flavivirus-naïve adults. Journal of Infectious Diseases 2015; 212: 702-12 [with editorial].
• Kirkpatrick BD, Colgate ER, Mychaleckyj JC, Haque R, Dickson DM, Carmolli MP, Nayak U, Taniuchi M, Naylor C, Qadri F, Ma JZ, Alam M, Walsh MC, Diehl SA, Petri WA Jr. The Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) study: Description of Methods of an Interventional Study Designed to Explore Complex Biological Problems. American Journal of Tropical Medicine and Hygiene 2015; 92 (4): 744-51.
• Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B., deSilva AD, Lindow JC, Whitehead SS, Durbin A, Kirkpatrick BD, Sette A. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes and are similar in magnitude and breadth to those following natural infection. Journal of Virology 2015; 89 (10): 120-128.
• Taniuchi M, Begum S, Uddin MJ, Platts-Mills JA, Liu J, Kirkpatrick BD, Chowdhury AH, Jamil KM, Haque R, Petri WA, Houpt E. Kinetics of polio shedding following oral vaccination as measured by qRT-PCR versus culture. Journal of Clinical Microniology 2015; 53 (1): 206-2011.
• Fimlaid KA, Lindow JC, Tribble DR, Bunn JY, Maue AC, Kirkpatrick BD. Peripheral CD4+ T Cell Cytokine Responses Following Human Challenge and Re-challenge with Campylobacter jejuni. PLOS ONE 2014; 9 (11) e112513: 1-8
• Haque R, Snider C, Ma Jennie, Liu Y, Nayak U, Mychaleckyj J, Korpe P, Mondal D, Kabir M, Alam M, Pallansch M, Kirkpatrick BD, Petri WA. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. Vaccine 2014; 32: 478-482.
• Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Fingar A, Poly F, Hoq F, Tribble DR. Lack of Homologous Protection Against Campylobacter jejuni CG8421 in a Human Challenge Model. Clinical Infectious Diseases. 2013; 57 (8): 1106-1113.
• Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose live attenuated dengue viruses leads to distinct immunologic and virologic profiles. Vaccine 2013; 31: 3347-52. PMC3777849
• Durbin AP*, Kirkpatrick BD,* Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. A Single Dose of Any Four Different Live Attenuated Tetravalent Dengue Vaccines is Safe and Immunogenic in Flavivirus-naïve Adults: A Randomized, Double Blind Clinical Trial. Journal of Infectious Disease. 2013; 207: 957-65. (*shared first author) PMC3571448
• Lindow JC, Fimlaid K, Bunn J, Durbin AP, Whitehead SS, Kirkpatrick BD. Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Pro-inflammatory, Multifunctional T Cell Response in Humans. PLOS Neglected Tropical Diseases. 2012; 6 (7): e1742. PMC3398956

All Kirkpatrick publications